Clear ×
Edesa Biotech, Inc. EDSA

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Oct 15, 2026 8-K 11 signals fired
Core
Secondary Endpoint Mentioned Clinical Trial Result Clinical Hold Patient Enrollment Velocity Lead Asset Progress Indication Expansion
Other
Interim Data Positive Publication Positive Patient Retention High Enrollment Ahead Of Schedule
Biotech Risk
Clinical Hold Active
Aug 20, 2026 8-K 37 signals fired · top 15
Other
Ipo Net Proceeds Disclosure Amendment Modification Waiver Clause Transfer And Demand Rights Limitations Market Price Definition Fcpa Compliance Representation Form S3 Shelf Registration Disclosure New York Jurisdiction Clause Use Of Proceeds Disclosure Hazardous Materials Definition Corporate Authority Representation Corporate Organization And Standing Representation Legal Opinion Methodology Disclosure Indemnification Consent Requirement Nyse Listing Disclosure No Regulatory Approval Required
Aug 13, 2026 10-Q 26 signals fired · top 15
Other
Rsu Psu Vesting Schedule Disclosed Warrant Valued Black Scholes Net Loss Reported Financing Activities Cash Flow Disclosure Equity Plan Share Reserve Disclosure Liquidity Position Snapshot Disclosed Cash Flow Statement Investing Activities Stock Option Grant Disclosed Form S3 Shelf Registration Disclosure Interim Data Positive Insider Buying Institutional Investment Protocol Amended
Core
Clinical Trial Result Combination Therapy Mentioned
Jun 11, 2026 8-K 27 signals fired · top 15
Other
Corporate Organization And Standing Representation Indemnification Consent Requirement Corporate Authority Representation Fcpa Compliance Representation Sanctions Compliance Representation Conflicted Defense Counsel Provision Form 8K Filing Disclosure Registration Rights Piggyback Provision Amendment Modification Waiver Clause Survival Of Representations Warranties Clause Market Price Definition Tax Advisor Consultation Urged Nyse Listing Disclosure
Core
Indication Expansion Lead Asset Progress
Jun 5, 2026 8-K 12 signals fired
Core
Clinical Trial Result Combination Therapy Mentioned Secondary Endpoint Mentioned
Other
Patient Retention High Interim Data Positive Expanded Access Program Active Fda Aligned Publication Positive Enrollment Ahead Of Schedule Mineral Exploration Delineation Fast Track Designation Received
Healthcare
Mlr Stable
May 29, 2026 8-K 5 signals fired
Other
Auditor Appointment Ratification Quorum Presence Disclosed Equity Plan Share Reserve Disclosure Classified Board Director Election Equity Award Plan Types Enumerated
May 14, 2026 10-Q 12 signals fired
Other
Rsu Psu Vesting Schedule Disclosed Warrant Valued Black Scholes Net Loss Reported Financing Activities Cash Flow Disclosure Equity Plan Share Reserve Disclosure Cash Flow Statement Investing Activities Liquidity Position Snapshot Disclosed Operating Lease Rent Expense Disclosed Stock Option Grant Disclosed Interim Data Positive
Core
Indication Expansion Clinical Trial Result